Tags

Type your tag names separated by a space and hit enter

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Abstract

Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ribavirin therapy is unknown. Viral load was measured in 22 chronic hepatitis C (genotype 1) patients before and 24 h after 9 MU IFN-alpha-2a (days 0 and 1), and before and during weekly 180 microg PEG-IFN-alpha-2a (days 7, 8, 11, 14 and 21) administration. Thereafter, ribavirin (800 mg/d) was added for 6 months. Virological responders continued treatment for a further 6 months. Twenty-eight patients treated with standard IFN/ribavirin therapy in a previous study using an analogous protocol served as historic controls. After 6 months 15 (68.2%) patients were (HCV-RNA) negative, eight of whom (36.4%) had a sustained response. The decrease in viral load 24 h after 9 MU IFN-alpha-2a was greater in virological responders (1.05 log [0.25-1.67]) than in nonresponders (NR) (0.34 [0.14-0.65]; P=0.003). In contrast, viral decline was not different between responders and NRs during the first 2 weeks on PEG-IFN-alpha-2a. All patients with an initial decline > 1.4 log became sustained responders. Five of 12 patients with a log change < 0.8 became end of treatment responders, two had a sustained response. Antiviral response to PEG-IFN-alpha-2a is different to that on standard IFN. In spite of a lower initial response PEG-IFN-alpha-2a/ribavirin combination therapy may overcome predicted IFN unresponsiveness.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria.

    , , , , , , ,

    Source

    Journal of viral hepatitis 10:1 2003 Jan pg 37-42

    MeSH

    Adult
    Antiviral Agents
    Drug Therapy, Combination
    Female
    Genotype
    Hepacivirus
    Hepatitis C, Chronic
    Humans
    Interferon alpha-2
    Interferon-alpha
    Male
    Middle Aged
    Polyethylene Glycols
    Recombinant Proteins
    Ribavirin
    Treatment Outcome
    Viral Load

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    12558910

    Citation

    Jessner, W, et al. "Early Viral Kinetics On Treatment With Pegylated Interferon-alpha-2a in Chronic Hepatitis C Virus Genotype 1 Infection." Journal of Viral Hepatitis, vol. 10, no. 1, 2003, pp. 37-42.
    Jessner W, Stauber R, Hackl F, et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat. 2003;10(1):37-42.
    Jessner, W., Stauber, R., Hackl, F., Datz, C., Watkins-Riedel, T., Hofer, H., ... Ferenci, P. (2003). Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. Journal of Viral Hepatitis, 10(1), pp. 37-42.
    Jessner W, et al. Early Viral Kinetics On Treatment With Pegylated Interferon-alpha-2a in Chronic Hepatitis C Virus Genotype 1 Infection. J Viral Hepat. 2003;10(1):37-42. PubMed PMID: 12558910.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. AU - Jessner,W, AU - Stauber,R, AU - Hackl,F, AU - Datz,C, AU - Watkins-Riedel,T, AU - Hofer,H, AU - Gangl,A, AU - Kessler,H, AU - Ferenci,P, PY - 2003/2/1/pubmed PY - 2003/5/28/medline PY - 2003/2/1/entrez SP - 37 EP - 42 JF - Journal of viral hepatitis JO - J. Viral Hepat. VL - 10 IS - 1 N2 - Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ribavirin therapy is unknown. Viral load was measured in 22 chronic hepatitis C (genotype 1) patients before and 24 h after 9 MU IFN-alpha-2a (days 0 and 1), and before and during weekly 180 microg PEG-IFN-alpha-2a (days 7, 8, 11, 14 and 21) administration. Thereafter, ribavirin (800 mg/d) was added for 6 months. Virological responders continued treatment for a further 6 months. Twenty-eight patients treated with standard IFN/ribavirin therapy in a previous study using an analogous protocol served as historic controls. After 6 months 15 (68.2%) patients were (HCV-RNA) negative, eight of whom (36.4%) had a sustained response. The decrease in viral load 24 h after 9 MU IFN-alpha-2a was greater in virological responders (1.05 log [0.25-1.67]) than in nonresponders (NR) (0.34 [0.14-0.65]; P=0.003). In contrast, viral decline was not different between responders and NRs during the first 2 weeks on PEG-IFN-alpha-2a. All patients with an initial decline > 1.4 log became sustained responders. Five of 12 patients with a log change < 0.8 became end of treatment responders, two had a sustained response. Antiviral response to PEG-IFN-alpha-2a is different to that on standard IFN. In spite of a lower initial response PEG-IFN-alpha-2a/ribavirin combination therapy may overcome predicted IFN unresponsiveness. SN - 1352-0504 UR - https://www.unboundmedicine.com/medline/citation/12558910/Early_viral_kinetics_on_treatment_with_pegylated_interferon_alpha_2a_in_chronic_hepatitis_C_virus_genotype_1_infection_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1352-0504&amp;date=2003&amp;volume=10&amp;issue=1&amp;spage=37 DB - PRIME DP - Unbound Medicine ER -